OncoMatch/Clinical Trials/NCT06856499
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
Is NCT06856499 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Cirtuvivint and Olaparib for endometrioid ovarian cancer.
Treatment: Cirtuvivint · Olaparib — The purpose of this study is to learn about the safety and tolerability of Cirtuvivint in combination with Olaparib in platinum resistant ovarian cancer. The study also aims to determine the recommended dose of the combination therapy. If a participant is a good fit for the study, and they enroll in the study, they will: * Visit the clinic often at the beginning of the study for physical exams, blood draws, vital signs, and other study and routine care procedures. After the first two months participants will visit the clinic every 28 days. * Take the study medications, Cirtuvivint and Olaparib. Participants will take Olaparib every day. Participants will either take Cirtuvivint 5 days per week or 2 days per week.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Allowed: BRCA1 mutation
Patients must have had testing for BRCA mutation (tumor or germline) and tumor HRD testing, and have been positive for one and/or the other.
Allowed: BRCA2 mutation
Patients must have had testing for BRCA mutation (tumor or germline) and tumor HRD testing, and have been positive for one and/or the other.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy
must have received at least one prior platinum-based chemotherapy regimen
Must have received: PARP inhibitor — treatment or maintenance
must have received a prior PARP inhibitor as either treatment or maintenance therapy
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L (1500/µL); platelet count ≥ 100 x 10^9/L (100,000/µL); hemoglobin ≥ 10.0 g/dL with no blood transfusion in past 28 days
Kidney function
serum creatinine ≤ 1.5 x ULN; creatinine clearance ≥51 mL/min (Cockcroft-Gault or 24h urine)
Liver function
AST/ALT ≤ 2.5 x ULN unless liver metastases are present in which case ≤ 5x ULN; serum bilirubin ≤ 1.5 x ULN (Gilbert syndrome eligible if total bilirubin < 3.0 x ULN); serum albumin ≥ 2 g/dL
adequate hematologic, liver, and kidney function as defined as: ANC ≥ 1.5 x 10^9/L (1500/µL); Platelet count ≥ 100 x 10^9/L (100,000 µL); Hemoglobin ≥ 10.0 g/dL with no blood transfusion in the past 28 days; Serum creatinine ≤ 1.5 x ULN; creatinine clearance ≥51 mL/min; AST/ALT ≤ 2.5 x ULN unless liver metastases are present in which case ≤ 5x ULN; serum bilirubin ≤ 1.5 x ULN (Gilbert syndrome eligible if total bilirubin < 3.0 x ULN); serum albumin ≥ 2 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- CU Medicine Clinics · Aurora, Colorado
- Universtiy of Colorado Hospital · Aurora, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify